Dec. 30 at 10:35 PM
$TLSA
They were at 17 patients in September and need to get to 54. Has anyone heard an update?
Tiziana’s Phase 2a trial of intranasal foralumab in non-active secondary progressive MS (SPMS) is not fully enrolled based on public data. On http://ClinicalTrials.gov (NCT06292923) and related trackers, the study is still listed as “Recruiting,” which usually means at least some sites remain open to new patients. The planned enrollment is about 54 participants. Public reporting earlier in 2025 suggested only a partial cohort had been enrolled and randomized at that time, supporting the idea that enrollment has been slower than initially planned.
The company’s decision to push the primary readout from Q4 2025 to H1 2026 is consistent with either ongoing enrollment, later patient dosing, or the need for more mature data before database lock. http://ClinicalTrials.gov does not post real-time enrollment counts, but the continued recruiting status is a key clue that enrollment is still ongoing.
